References
- Krowka MJ. Evolving dilemmas and management of portopulmonary hypertension. Semin Liver Dis 2006;26:265–72.
- Salvi SS. a1-adrenergic hypothesis for pulmonary hypertension. Chest 1999;115:1708–19.
- Salvi SS. Liver disease and pulmonary hypertension. Gut 2000;47:595.
- Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, Deleterious effects of β-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006;130:120–6.
- Lewczuk J, Piszko P, Jagas J, Wrabec K. Impact of a 30 day therapy with doxazosin-alpha1 adrenergic blocker on pulmonary hemodynamics in patients with secondary pulmonary hypertension due to chronic obstructive pulmonary disease. Pol Merkur Lecarski 2005;18:279–81.
- Farzaneh-Far R, McKeown BH, Dang D, Roberts J, Schiller NB, Foster E. Accuracy of Doppler-estimated pulmonary vascular resistance in patients before liver transplantation. Am J Cardiol 2008;101:259–62.
- Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, Wiesner RH. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453–8.
- Albillos A, Lledo JL, Banares R, Rossi I, Iborra J, Calleja JL, Hemodynamic effects of a1-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994;20:611–17.
- Oriowo MA, Chandrasekhar B, Kadavil EA. Alpha 1-adrenoreceptor subtypes mediating noradrenaline-induced contraction of pulmonary artery from pulmonary hypertensive rats. Eur J Pharmacol 2003;482:255–63.
- Salcedo A, Garijo J, Monge L, Fernandez N, Garcia-Villalon AL, Turrion VS, Adrenergic response of splanchnic arteries from cirrhotic patients: role of nitric oxide, prostanoids, and reactive oxygen species. Exp Biol Med (Maywood) 2007;232:1360–7.